Mangoceuticals (MGRX) Stock Price, News & Analysis

Company Overview

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.

Key Stats

• Today's Range: $2.59 to $2.73
• 50-Day Range: $2.31 to $2.72
• 52-Week Range: $2.07 to $16.80
• Volume: 38,847 shs
• Average Volume: 93,428 shs
• Market Capitalization: $6.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Mangoceuticals Stock Analysis - MarketRank™

Mangoceuticals scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Mangoceuticals.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Mangoceuticals is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mangoceuticals is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mangoceuticals has a P/B Ratio of 4.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.43% of the float of Mangoceuticals has been sold short.

Short Interest Ratio / Days to Cover

Mangoceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mangoceuticals has recently decreased by 23.13%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mangoceuticals does not currently pay a dividend.

Dividend Growth

Mangoceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.43% of the float of Mangoceuticals has been sold short.

Short Interest Ratio / Days to Cover

Mangoceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mangoceuticals has recently decreased by 23.13%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

Mangoceuticals has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mangoceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

39.30% of the stock of Mangoceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

56.72% of the stock of Mangoceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MGRX Stock Analysis - Frequently Asked Questions

How have MGRX shares performed this year?

Mangoceuticals' stock was trading at $2.42 at the beginning of 2025. Since then, MGRX stock has increased by 7.9% and is now trading at $2.61.
View the best growth stocks for 2025 here.

When did Mangoceuticals' stock split?

Shares of Mangoceuticals reverse split before market open on Wednesday, October 16th 2024. The 1-15 reverse split was announced on Wednesday, October 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Mangoceuticals IPO?

Mangoceuticals (MGRX) raised $5 million in an initial public offering (IPO) on Tuesday, March 21st 2023. The company issued 1,300,000 shares at $4.00 per share. Boustead Securities served as the underwriter for the IPO.

How do I buy shares of Mangoceuticals?

Shares of MGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Mangoceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mangoceuticals investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), NVIDIA (NVDA), MSP Recovery (LIFW), MSP Recovery (LIFW), Advanced Micro Devices (AMD).

Company Calendar

• Today: 1/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Miscellaneous health & allied services, not elsewhere classified
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:MGRX
• CUSIP: N/A
• CIK: 1938046
• Web: www.mangorx.com
• Phone: 833-626-4679
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($5.7876)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-9,210,000.00
• Net Margins: -1,237.00%
• Pretax Margin: -1,237.00%
• Return on Equity: -138.00%
• Return on Assets: -118.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.07
• Quick Ratio: 0.07

Sales & Book Value

• Annual Sales: $730,000.00
• Price / Sales: 8.90
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.54 per share
• Price / Book: 4.83

Miscellaneous

• Outstanding Shares: 2,490,000
• Free Float: 1,510,000
• Market Cap: $6.50 million
• Optionable: Not Optionable
• Beta: 1.94